Aims: To evaluate the role of hormonal contraceptives as a risk factor of high-risk human papillomavirus (HR-HPV), cervical intraepithelial lesions (CIN) and cervical cancer in our multi-center population-based LAMS (Latin American Screening) study. Methods: A cohort study with >12,000 women from Brazil and Argentina using logistic regression to analyze the covariates of hormonal contraception (HOC – oral, injections, patches, implants, vaginal ring and progesterone intrauterine system) use followed by multivariate modeling for predictors of HR-HPV and CIN2+. Results: HR-HPV infection was a consistent risk factor of high-grade CIN in all three groups of women. The length of HOC use was not significantly related to high-grade squamous intraepithelial lesions (HSIL)+ Pap (p = 0.069), LSIL+ Pap (p = 0.781) or ASCUS+ (p = 0.231). The same was true with the length of HOC use and histology CIN3+ (p = 0.115) and CIN2+ (p = 0.515). Frequently, HOC users have previously shown more HPV-related lesions, as well as lower HPV prevalence if they were current smokers. But HOC use and time of usage were not independent risk factors of either HR-HPV infection or high-grade CIN using multiple logistic regressions. Conclusions: No evidence was found for an association between the use of HOC with an increased risk for HR-HPV infection or high-grade CIN in this cohort.

Keywords:
Hormonal contraceptives, Cervical intraepithelial lesions, High-risk human papillomavirus, Cohort study
1.
Castellsagué X, Muñoz N: Chapter 3: cofactors in human papillomavirus carcinogenesis – role of parity, oral contraceptives, and tobacco smoking. Natl Cancer Inst Monogr 2003;31:20–28.
2.
Smith JS, Green J, Berrington de Gonzalez A, Appleby P, Peto J, Plummer M, Franceschi S, Beral V: Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 2003;361:1159–1167.
3.
Bosch FX, de Sanjosé S: The epidemiology of human papillomavirus infection and cervical cancer. Dis Markers 2007;23:213–227.
4.
Peto J, Gilham C, Fletcher O, Matthews FE: The cervical cancer epidemic that screening has prevented in the UK. Lancet 2004;364:249–256.
5.
Syrjänen K, Shabalova I, Petrovichev N, Kozachenko V, Zakharova T, Pajanidi J, Podistov J, Chemeris G, Sozaeva L, Lipova E, Tsidaeva I, Ivanchenko O, Pshepurko A, Zakharenko S, Nerovjna R, Kljukina L, Erokhina O, Branovskaja M, Nikitina M, Grunberga V, Grunberg A, Juschenko A, Santopietro R, Cintorino M, Tosi P, Syrjanen S: Oral contraceptives are not an independent risk factor for cervical intraepithelial neoplasia or high-risk human papillomavirus infections. Anticancer Res 2006;26:4729–4740.
6.
Syrjänen S, Shabalova I, Petrovichev N, Kozachenko V, Zakharova T, Pajanidi J, Podistov J, Chemeris G, Sozaeva L, Lipova E, Tsidaeva I, Ivanchenko O, Pshepurko A, Zakharenko S, Nerovjna R, Kljukina L, Erokhina O, Branovskaja M, Nikitina M, Grunberga V, Grunberg A, Juschenko A, Cintorino M, Santopietro R, Tosi P, Syrjänen K: Factors predicting persistence of high-risk human papillomavirus (HPV) infections in women prospectively followed-up in three New Independent States (NIS) of the former Soviet Union. Eur J Gynaecol Oncol 2005;26:491–498.
7.
Eluf-Neto J, Booth M, Muñoz N, Bosch FX, Meijer CJ, Walboomers JM: Human papillomavirus and invasive cervical cancer in Brazil. Br J Cancer 1994;69:114–119.
8.
Rousseau MC, Franco EL, Villa LL, Sobrinho JP, Termini L, Prado JM, Rohan TE: A cumulative case-control study of risk factor profiles for oncogenic and nononcogenic cervical human papillomavirus infections. Cancer Epidemiol Biomarkers Prev 2000;9:469–476.
9.
Yang BH, Bray FI, Parkin DM, Sellors JW, Zhang ZF: Cervical cancer as a priority for prevention in different world regions: an evaluation using years of life lost. Int J Cancer 2004;109:418–424.
10.
Syrjänen K Naud P, Derchain SM, Roteli-Martins C, Longatto-Filho A, Tatti S, Branca M, Eržen M, Serpa-Hammes L, Matos J, Gontijo R, Sarian L, Lima TP, Maeda MYS, Lörincz A, Dores GB, Costa S, Syrjänen S: Comparing PAP smear cytology, aided visual inspection, screening colposcopy, cervicography and HPV testing as optional screening tools in Latin America. Study design and baseline data of the LAMS Study. Anticancer Res 2005;25:3469–3480.
11.
Longatto-Filho A, Maeda MYS, Eržen M, Branca M, Roteli-Martins C, Naud P, Derchain SM, Serpa-Hammes L, Matos J, Gontijo R, Sarian L, Lima TP, Tatti S, Syrjänen S, Syrjänen K: Conventional PAP smear and liquid-based cytology as screening tools in low-resource settings of Latin America. Experience of the Latin American Screening Study. Acta Cytol 2005;49:500–506.
12.
Sarian L Derchain SM, Naud P, Roteli-Martins C, Longatto-Filho A, Tatti S, Branca M, Eržen M, Serpa-Hammes L, Matos J, Gontijo R, Lima TP, Maeda MYS, Lörincz A, Dores GB, Costa S, Syrjänen S, Syrjänen K: Evaluation of visual inspection with acetic acid (VIA), Lugol’s iodine (VILI) cervical cytology and HPV testing as cervical screening tools in Latin America. This report refers to partial results from the LAMS (Latin American Screening) study. J Med Screen 2005;12:142–149.
13.
Longatto-Filho A, Eržen M, Branca M, Roteli-Martins C, Naud P, Derchain S, Hammes L, Sarian LO, Matos J, Gontijo R, Lima T, Maeda MYS, Tatti S, Syrjänen S, Dores G, Lörincz A, Syrjänen K: Human papillomavirus (HPV) testing as an optional screening tool in low-resource settings of Latin America. Experience from the LAMS Study. Int J Gynecol Cancer 2006;16:955–962.
14.
Longatto-Filho A, Roteli-Martins C, Hammes L, Etlinger D, Pereira SM, Eržen M, Branca M, Naud P, Derchain, SF, Sarian LO, Matos J, Gontijo R, Lima T, Maeda MY, Tatti S, Syrjänen S, Syrjänen K: Self-sampling for human papillomavirus (HPV) testing as cervical cancer screening option. Experience from the LAMS Study. Eur J Gynaecol Oncol 2008;29:327–332.
15.
Hammes LS, Naud P, Passos E, Rivoire W, Matos J, Brouwers K, Syrjänen KJ: Value of the International Federation of Colposcopy and Cervical Pathology (IFCPC) terminology in predicting cervical pathology. J Lower Genital Tract Dis 2007;11:158–165.
16.
Solomon D, Nayar R: The Bethesda system for reporting cervical cytology: definitions, criteria and explanatory notes, ed 2. New York, Springler Verlag, 2004, pp 1–190.
17.
International Collaboration of Epidemiological Studies of Cervical Cancer, Appleby P, Beral V, Berrington de González A, Colin D, Franceschi S, Goodhill A, Green J, Peto J, Plummer M, Sweetland S: Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet 2007;370:1609–621.
18.
Sasieni P: Cervical cancer prevention and hormonal contraception. Lancet 2007;370:1591–1592.
19.
International Collaboration of Epidemiological Studies of Cervical Cancer, Appleby P, Beral V, Berrington de González A, Colin D, Franceschi S, Goodill A, Green J, Peto J, Plummer M, Sweetland S: Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer 2006;118:1481–1495.
20.
Vessey M, Painter R: Oral contraceptive use and cancer. Findings in a large cohort study, 1968–2004. Br J Cancer 2006;95:385–389.
21.
Moreno V, Bosch FX, Muñoz N, Meijer CJ, Shah KV, Walboomers JM, Herrero R, Franceschi S: International Agency for Research on Cancer. Multicentric Cervical Cancer Study Group. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet 2002;359:1085–1092.
22.
Vaccarella S, Herrero R, Dai M, Snijders PJ, Meijer CJ, Thomas JO, Hoang Anh PT, Ferreccio C, Matos E, Posso H, de Sanjosé S, Shin HR, Sukvirach S, Lazcano-Ponce E, Ronco G, Rajkumar R, Qiao YL, Muñoz N, Franceschi S: Reproductive factors, oral contraceptive use, and human papillomavirus infection: pooled analysis of the IARC HPV prevalence surveys. Cancer Epidemiol Biomarkers Prev 2006;15:2148–2153.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.